Filtered By:
Specialty: Cardiology
Drug: Colcrys
This page shows you your search results in order of date.
Order by Relevance | Date
Total 39 results found since Jan 2013.
Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week
J Am Coll Cardiol. 2023 Aug 15;82(7):648-660. doi: 10.1016/j.jacc.2023.05.055.ABSTRACTAmong statin-treated patients, inflammation assessed by means of high-sensitivity C-reactive protein (hsCRP) is a more powerful determinant of cardiovascular death and all-cause mortality than low-density-lipoprotein cholesterol (LDL-C). Several therapies that target residual inflammatory risk significantly reduce vascular event rates. For coronary artery disease patients already taking guideline-directed medical care, including statins, low-dose colchicine (0.5 mg/d orally) has been shown to safely lower major adverse cardiovascular even...
Source: Atherosclerosis - August 9, 2023 Category: Cardiology Authors: Kyle Nelson Valentin Fuster Paul M Ridker Source Type: research
Anti-inflammatory therapies were associated with reduced risk of myocardial infarction in patients with established cardiovascular disease or high cardiovascular risks: A systematic review and meta-analysis of randomized controlled trials
CONCLUSIONS: Anti-inflammatory therapies, especially those targeting the central IL-6 signaling pathway, may serve as promising treating strategies to ameliorate the risk of MI. IL-1 inhibitor and colchicine were associated with decreased risks of heart failure and stroke, respectively. MI risk reduction by anti-inflammatory therapies seemed to be more prominent in older patients with long follow-up duration.PMID:37527612 | DOI:10.1016/j.atherosclerosis.2023.06.972
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: Zonglin Li Chu Lin Xiaoling Cai Suiyuan Hu Fang Lv Wenjia Yang Xingyun Zhu Linong Ji Source Type: research
A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease
ConclusionsColchicine is an effective, relatively safe drug that could be considered for the treatment of CAD. However, we need to pay attention to the increasing occurrence of non-cardiovascular mortality and infection especially pneumonia possibly caused by colchicine.Graphical abstractEfficacy and safety of colchicine for patients with CAD.CAD coronary artery disease;RCTs randomized controlled trials;OR odds ratio;MACEs major adverse cardiovascular events;ACS acute coronary syndrome;NNT number needed to treat;NNH number needed to harm
Source: Clinical Research in Cardiology - July 28, 2023 Category: Cardiology Source Type: research
Insights into the Role of Inflammation in the Management of Atherosclerosis
J Inflamm Res. 2023 May 24;16:2223-2239. doi: 10.2147/JIR.S276982. eCollection 2023.ABSTRACTAtherosclerosis is the biological basis of ischemic heart disease and ischemic stroke, the leading causes of death in the world. After decades of studies, the understanding of atherosclerosis has evolved dramatically, and inflammation has been recognized as one of the most relevant pillars in all phases of atherosclerotic disease. Nevertheless, only recently, the trial CANTOS, and subsequent outcome studies with colchicine, finally provided proof-of-concept evidence that anti-inflammatory therapies were able to reduce cardiovascular...
Source: Atherosclerosis - May 30, 2023 Category: Cardiology Authors: Viviane Zorzanelli Rocha Fabiana Hanna Rached Marcio Hiroshi Miname Source Type: research
Lipoprotein (a), Inflammation, and Atherosclerosis
J Clin Med. 2023 Mar 27;12(7):2529. doi: 10.3390/jcm12072529.ABSTRACTGrowing evidence has shown that high levels of lipoprotein (a) (Lp(a)) and chronic inflammation may be responsible for the residual risk of cardiovascular events in patients managed with an optimal evidence-based approach. Clinical studies have demonstrated a correlation between higher Lp(a) levels and several atherosclerotic diseases including ischemic heart disease, stroke, and degenerative calcific aortic stenosis. The threshold value of Lp(a) serum concentrations associated with a significantly increased cardiovascular risk is >125 nmol/L (50 mg/dL...
Source: Atherosclerosis - April 13, 2023 Category: Cardiology Authors: Stefania Angela Di Fusco Aldo Pietro Maggioni Pietro Scicchitano Marco Zuin Emilia D'Elia Furio Colivicchi Source Type: research
Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence
Int J Mol Sci. 2023 Jan 27;24(3):2483. doi: 10.3390/ijms24032483.ABSTRACTSeveral lines of evidence have clearly indicated that inflammation plays a pivotal role in the development of atherosclerosis and of its thrombotic complications such as acute coronary syndromes or ischemic stroke. Thus, it has been postulated that the use of anti-inflammatory agents might be extremely useful to improve cardiovascular outcome. Recently, increasing attention has been reserved to one of the oldest plant-derived drugs still in use in clinical practice, colchicine that has been used as drug to treat inflammatory diseases such gout or Medi...
Source: Atherosclerosis - February 11, 2023 Category: Cardiology Authors: Giovanni Cimmino Francesco S Loffredo Gennaro De Rosa Plinio Cirillo Source Type: research
The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes
Eur Heart J Cardiovasc Pharmacother. 2023 Jan 13:pvad005. doi: 10.1093/ehjcvp/pvad005. Online ahead of print.ABSTRACTIn type 1 diabetes, average life expectancy is reduced by more than 10 years as compared with outside of diabetes. Residual cardiovascular risk defines high cardiovascular event rate despite modern, guideline-recommended standard of care of established risk factors like hypertension, dyslipidaemia, and glycaemic control, and it adds importantly to these lost years of life in type 1 diabetes due to atherosclerotic cardiovascular disease like myocardial infarction and ischaemic stroke. With growing understandi...
Source: Atherosclerosis - January 13, 2023 Category: Cardiology Authors: Nicklas J ärvelä Johansen Filip Krag Knop Source Type: research
Colchicine in the Management of Acute Coronary Syndrome: A Meta-analysis
ConclusionsThese data suggest colchicine, in addition to guideline-directed medical therapy following acute coronary syndrome reduces MACE, cerebrovascular accidents, and rates of urgent revascularization at 2 years of follow-up.
Source: Cardiology and Therapy - January 6, 2023 Category: Cardiology Source Type: research
Evaluating the Utility of Colchicine in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
Abstract:
Colchicine has demonstrated promising effects in inhibiting local and systemic inflammation during acute coronary syndrome (ACS). However, the efficacy of colchicine in ACS is controversial. We performed a meta-analysis to assess the utility of colchicine in ACS by systematically searching randomized controlled trials. Recurrent myocardial infarction, coronary revascularization, and stroke were included as efficacy endpoint parameters whereas safety endpoints chosen were all-cause mortality, cardiovascular mortality, infectious events, and gastrointestinal (GI) adverse events. Nine identified studies were inc...
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Review Article Source Type: research
The use of colchicine as an anti-inflammatory agent for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis
CONCLUSIONS: The use of colchicine reduces the risk of stroke in patients with a history of coronary artery disease, without a significant increase in gastrointestinal and myopathy/myalgia adverse effects.PMID:35538274 | DOI:10.1007/s11239-022-02659-9
Source: Atherosclerosis - May 10, 2022 Category: Cardiology Authors: Claire X Y Goh Ying Kiat Tan Choon Han Tan Aloysius S T Leow Jamie S Y Ho Natalie H W Tan Sherill Goh Andrew F W Ho Vijay K Sharma Bernard P L Chan Leonard L L Yeo Benjamin Y Q Tan Source Type: research
Effect of Treatment with Colchicine after Acute Coronary Syndrome on Major Cardiovascular Events: A Systematic Review and Meta-Analysis of Clinical Trials
CONCLUSION: Colchicine has shown some molecular and clinical promising results in ACS patients. The lack of effect of colchicine on MI and all-cause mortality can be partly attributed to the limitations of previous studies. Since colchicine is an inexpensive and easy-to-access drug that has shown to be safe in low-dose regimens in the clinical setting; it would be worthy that future large-scale well-designed clinical trials address this issue by resolving the limitations of previous investigations.PMID:35495414 | PMC:PMC9020977 | DOI:10.1155/2022/8317011
Source: Atherosclerosis - May 2, 2022 Category: Cardiology Authors: Erfan Razavi Akam Ramezani Asma Kazemi Armin Attar Source Type: research
